HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Oversight Among Hot Button Issues In 112th Congress

This article was originally published in The Tan Sheet

Executive Summary

Health care reform and oversight of FDA remain hot button issues in the 112th Congress, industry advocates say.

You may also be interested in...

Sharfstein Leaving FDA: What Does It Mean? Consider The Source

The departure may help position the agency now that it faces a Republican majority in the House.

OTC, Supplement Industry Groups Target Returning Consumer Choice In Health Savings Accounts

A federal agency's decision against extending a delay on requiring prescriptions for OTC drugs bought with pre-tax medical expense accounts galvanizes the consumer health care product industry's resolve to repeal the change.

Rolaids Recall Puts Contract Manufacturers In Issa's Crosshairs

Rep. Darrell Issa's questions on what FDA knew about the third-party manufacturer of a product Johnson & Johnson recently recalled reflect the accountability the incoming Oversight and Government Reform Committee chairman will demand from the agency.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts